The addition of macitentan to the BRAF inhibitor reduced the expression of EDNRA within the tumours (Fig 8F), suggesting that through its affinity for EDNRA macitentan targets the AXL/EDNRA‐expressing cells. The gene discussed is BRAF; the disease is neoplasm.